---

$2.92

+0.1240 ( +4.43% ) 185.3K

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2024-02-05	Sale	-239731.00	HAMED KAMAL
2024-02-05	Sale	-239731.00	JOSEPH TAMARA L
2024-02-05	Sale	-239731.00	Keutzer Timothy
2024-02-05	Sale	-63795.00	Mahadevia Ankit
2024-02-05	Sale	-679501.00	Shukla Sath
2024-01-04	Sale	-35604.00	Tregoning Kathleen
2023-11-15	Sale	-300000.00	Rajavelu Esther
2023-10-10	Sale	-20000.00	Pottage John C Jr
2023-10-10	Sale	-20000.00	Smith Cynthia
2023-10-10	Sale	-20000.00	Jackson Scott Thomas